4
Changes in Ownership
Jade Biosciences, Inc. Filed Acc 0001415889-23-007247
CHIEF EXECUTIVE OFFICER sold 15,693 shares at an average $20.63 ($323,745)
- CHIEF EXECUTIVE OFFICER acquired 15,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
NOYES TIMOTHY P · CHIEF EXECUTIVE OFFICER
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-05-01 | Exercise or conversion : show line 1 in the form 10b5-1 | +15,000 | $2.14 | $32,100 | 15,693 | D |
| 2023-05-01 | Sale : show line 2 in the form 10b5-1 | −15,000 | $20.61 | $309,089 | 693 | D |
| 2023-05-02 | Sale : show line 3 in the form 10b5-1 | −693 | $21.15 | $14,657 | 0 | D |
| Open-market sales · 15,693 sh · avg $20.63 · $323,745 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2023-05-01 | Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (Right to Buy) | −15,000 | $2.14 | 2031-04-01 | 15,000 | 403,381 | D |
Loading xslF345X04/form4-05032023_060501.xml…